The life sciences division of tech major NEC Corporation has bought immuno-oncology assets from Swiss-German biotech Vaximm, for an undisclosed amount. 8 March 2022
London-listed Poolbeg Pharma has signed an agreement with OneThree Biotech to identify new drug targets and treatments for respiratory syncytial virus (RSV). 24 February 2022
In this episode, we look at the potential impact of decentralized clinical trials, as increasing adoption of this kind of study forms part of a general movement 10 February 2022
In another example of the growing popularity of the SPAC merger, digital medicine company Akili Interactive is to list on the Nasdaq in this way, with the deal 26 January 2022
2014-founded AI specialist InstaDeep has raised $100 million in a series B funding round, led by Alpha Intelligence Capital, together with CDIB. 25 January 2022
California-based insitro, a machine learning-driven drug discovery and development company, has announced the expansion of its leadership team. 12 January 2022
In what is an increasingly busy period for artificial intelligence (AI) research, privately-held AI company Iktos has agreed to work with South Korean biotech A 7 January 2022
Building on a long and growing list of collaborations, artificial intelligence (AI) firm Exscientia has agreed terms for a new deal with Sanofi. 7 January 2022
Biotech major Amgen and Generate Biomedicines have announced a research collaboration agreement to discover and create protein therapeutics for five clinical ta 6 January 2022
PhoreMost, a UK-based biopharma dedicated to developing drugs against intractable disease targets, has announced a collaboration to study oncology targets curre 5 January 2022
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episo 30 December 2021
Research from British online pharmacy Chemist4U has revealed some insights on the current state of prescriptions in England, including the most prescribed medic 22 December 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.